Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Bexaroten (ATC-Code: L01XF03) innerhalb des Zeitraumes vom 01.11.2026 bis zum 31.10.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

For the active ingredient Bexarotene (ATC code: L01XF03), AOK Niedersachsen. The health insurance fund offers, for the period until the entry into force of exclusive agreements as a result of a formal award procedure in accordance with the rules of Part 4 of the GWB, to all interested pharmaceutical companies, without any selection decision, discount agreements. The contracts are concluded within the framework of an “open-house model” and serve as a bridge between the start of generic competition (expiry of the patent) and the award of exclusive agreements. The agreements offered are not exclusive; contracts with all market participants (pharmaceutical companies) are desired by AOK Niedersachsen. Under the open-house model, uniform conditions apply to all participants. Contract content, terms and access procedures are uniform—individual negotiations are generally not conducted. The contract terms are a maximum of twenty-four months; the earliest possible start date is 01.11.2026. All contracts end no later than 31.10.2028, regardless of the date of the respective contract conclusion. Accession and/or contract conclusion may take place within the twenty-four-month period, each…

TENDER BRIEF

TENDER DOCUMENTS